BEVERLY, MA–(Marketwired – October 21, 2015) - Cellceutix Corporation (CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications today announced that it will hold its 2015 Annual Meeting of Stockholders on Tuesday, December 15, 2015. The meeting will be Cellceutix’s first annual meeting as a public company.
The meeting will be held at 100 Cummings Center, Suite 221-E, located in Beverly, Massachusetts and will convene at 10:00 a.m. local time. The record date for the meeting is October 22, 2015. At the meeting, the Company’s stockholders will be asked to elect five nominees to the Company’s Board of Directors, ratify the appointment of the Company’s independent registered public accounting firm, and approve, on an advisory basis, the compensation of the Company’s named executive officers. The Company also anticipates holding an advisory vote on the frequency of future votes on the Company’s executive compensation.
World Anti-Microbial Resistance Congress Washington, D.C.
We wish also to inform shareholders that at yesterday’s World Anti-Microbial Resistance Congress Washington, D.C., there was a last minute scheduling change andDr. Krishna Menon, was requested by organizers of the event to be part of the panel discussion titled “Resistance in Antibiotics- Panel Discussion Animal Feeding of Antibiotics” 10.00 AM to 12.00 Noon. We apologize that Dr. Menon could not give his planned presentation at 11AM on Brilacidin, but it was outside his control. Cellceutix will make the Brilacidin presentation available in the coming week.